

Supplementary Figure 1. Mitochondrial function in liver non-cancer and tumor cells. Mitochondrial stress test in whole cells using oligomycin (2μM), BAM15 (2μM), Antimycin A (10μM), and Rotenone (1μM) as indicated. Oxygen consumption rate (OCR) **(a)** normalized to protein or **(b)** normalized to basal OCR and **(c)** mitochondrial spare respiratory capacity in non-cancerous cells (primary murine hepatocytes and the immortalized human liver cell line PH5CH8), human liver cancer cell lines (HepG2 and Huh7), and murine liver cancer cell lines (Hepa1-6 and Hepa1c1c7). Extra-cellular acidification rate (ECAR) **(d)** normalized to protein or **(e)** normalized to basal ECAR. **(f)** Ratio of OCR to ECAR (OCR/ECAR) (n=3 independent experiments). Data are represented as mean ± SEM.



Supplementary Figure 2. Cleaved CASP3 staining, inflammation, and antioxidant status in livers of DEN-treated Flox and LDKO mice. (a) Representative images and (b) quantification of cleaved Casp3 immunohistochemical staining in livers of DEN-treated Flox and LDKO mice at 40w of age, scale bars=50 μm. (c) Representative H&E-stained livers from Flox and LDKO mice depicting inflammatory cell infiltration, scale bars = 50 μm. For **a-c**, n=10 Flox and 11 LDKO mice. (d) 8-OHdG levels of DNA isolated from Flox and LDKO liver tissue 24h after DEN treatment. (e) GSH:GSSG ratios and (f) NADPH levels in liver tissue of Flox and LDKO mice 24h after DEN treatment. For d-f, n=4 mice. * indicates significant difference, p < 0.05 as determined by two-tailed t-test (d was analyzed by one-way ANOVA followed by Tukey's post hoc analysis). Data are represented as mean ± SEM.



Supplementary Figure 3. Analysis of specific lipid species and lipid-related metabolites. Levels of (a) fatty acid species, (b) metabolites involved in phospholipid metabolism, (c) phospholipid (PC=phosphatidylcholine, PE=phosphatidylethanolamine, PI=phosphatidylinositol) species, (d) metabolites involved in glycerolipid metabolism, (e) glycerolipid species, (f) metabolites involved in sphingolipid metabolism and (g) sphingolipid species in livers of DEN-treated Flox and LDKO mice at 40w of age. * indicates significant difference from Flox, p < 0.05 (n=6 mice) as determined by Welch's two-tailed t-test. Data are represented as mean.



Supplementary Figure 4. Effect of ACC inhibition on lipid transporter expression and effect of acute DEN on antioxidant status. (a) Western blot and (b) quantification of LPL protein expression and mRNA expression of (c) *Lpl*, (d) *Cd36* and (e) *Fatp5* in livers of DEN-treated Flox and LDKO mice at 40w of age. (f) 8-OHdG levels of DNA isolated from Flox and LDKO liver tissue 24h after DEN treatment. (g) GSH:GSSG ratios and (h) NADPH levels in liver tissue of Flox and LDKO mice 24h after DEN treatment. * indicates significant difference, p < 0.05 as determined by two-tailed t-test (f was analyzed by one-way ANOVA followed by Tukey's post hoc analysis) n=4 mice. Data are represented as mean ± SEM.



Supplementary Figure 5. Uncropped Western blots. (a) Western blot of pan-ACC and (b) ponceau stain corresponding to Figure 2d. Western blots of (c) LPL and (d) β -actin

corresponding to Supplementary Figure 4a.